Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 years and above.~* Diagnosis of AD as defined by the Hanifin and Rajka 1980 criteria for AD.~* History of AD for ≥1 year.~* AD involvement of 5-50% treatable body surface area at screening and at baseline (excluding scalp).~* Disease severity graded as mild to severe according to vIGA-AD (i.e. vIGA-AD ≥2) at screening and baseline.~Key Exclusion Criteria:~* AD lesion(s) on scalp at screening and/or baseline.~* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea, urticaria, or psoriasis.~* Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of AD.~* Use of tanning beds or phototherapy within 4 weeks prior to baseline.~* Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline.~* Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase-4 inhibitors, or oral antibiotics within 2 weeks prior to baseline.~* Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e. the subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.~* Receipt of live attenuated vaccines within 4 weeks prior to baseline.~* Treatment with any marketed or investigational biologic agents within 6 months or 5 half-lives prior to baseline, or until cell counts return to normal, whichever is longer.~* History of any active skin infection within 1 week prior to baseline.~* Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Delgocitinib cream 1 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 3 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 8 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 20 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream vehicle (Type: PLACEBO_COMPARATOR): Delgocitinib cream vehicle applied twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).